Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors.

J Neuroimmune Pharmacol · 2014 · PMC4122817 · PMID 24789302

Europe PMC DOI

hedged sentences

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

did not quite reach significancep = 0.055so close (0.05 < p ≤ 0.1)

There was also a significant effect of MW181 on IL-6 levels in LPS-treated WT mice (F (2, 47) = 5,808; p = 0.0056); again, 20 mg/kg of MW181 inhibited IL-6 levels ( p = 0.0071), but the inhibition by MW181 at 5 mg/kg did not quite reach significance ( p = 0.055).

also in 350 other papers

showed a trendno p-value reported

MW181 at 20 mg/kg suppressed IL-1β levels in LPS-challenged mice ( p = 0.031), and at 5 mg/kg showed a trend, but when corrected for multiple comparisons the decrease did not reach significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.